Vietnamese Insights into Cognitive Aging Program (VIP): Objectives, study design, and cohort description

2024-7-1

APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in <i>APOE</i> ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics

2024-7-1

Comparing research attitudes in Down syndrome and non‐Down syndrome research decision‐makers

2024-7-1

Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof‐of‐principle study and call to action

2024-7-1

Anti‐epileptic drug use and subsequent degenerative dementia occurrence

2024-7-1

Correction to “The functional role of the pulvinar in discriminating between objective and subjective cognitive impairment in major depressive disorder”

2024-7-1

Personalized goals of people living with dementia and family carers: A content analysis of goals set within an individually tailored psychosocial intervention trial

2024-7-1

Practical social media recommendations for dementia prevention researchers

2024-7-1

Dementia severity at incident diagnosis in a population representative sample of older Americans

2024-7-1

Rural‐Urban mild cognitive impairment comparison in West Michigan through EHR

2024-7-1

Assessing social connection for long‐term care home residents: Systematic review using COnsensus‐based Standards for the selection of health Measurement INstruments guidelines

2024-7-1

Genetically proxied IL‐6 signaling and risk of Alzheimer's disease and lobar intracerebral hemorrhage: A drug target Mendelian randomization study

2024-7-1

Issue Information

2024-7-1

Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease

2024-7-1

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients

2024-7-1

Meaningful benefit of disease‐modifying treatment: Evaluating changes in health‐related resource use

2024-7-1

The AUstralian multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention study (AU‐ARROW): A study protocol for a single‐blind, multi‐site, randomized controlled trial

2024-4-1

Genetic associations with psychosis and affective disturbance in Alzheimer's disease

2024-4-1

Hearing loss and cognitive decline: Prioritizing equity in a world in which hearing health matters

2024-4-1

Alzheimer's disease drug development pipeline: 2024

2024-4-1

Recruiting a prospective community cohort to study Alzheimer's disease and structural and social determinants of health among adults racialized as Black: The ARCHES cohort

2024-4-1

Correction to “Masking the transmembrane region of the amyloid β precursor protein as a safe means to lower amyloid β production”

2024-4-1

A service‐oriented approach to clinical trial recruitment for dementia and brain health: Methods and case examples of MyAlliance for Brain Health

2024-4-1

Induction of tauopathy in a mouse model of amyloidosis using intravenous administration of adeno‐associated virus vectors expressing human P301L tau

2024-4-1

Discrepancies between self‐ and proxy‐rated quality of life in people living with dementia

2024-4-1

Using concept mapping to identify recruitment and engagement strategies for inclusion of LGBTQIA+ populations in Alzheimer's disease and related dementia research

2024-4-1

Issue Information

2024-4-1

Livestream, group movement program for people living with cognitive impairment and care partners: A randomized clinical trial

2024-4-1

Genetic and multi‐omic risk assessment of Alzheimer's disease implicates core associated biological domains

2024-4-1

Sex differences in Alzheimer's disease blood biomarkers in a Caribbean population of African ancestry: The Tobago Health Study

2024-4-1

Sex, gender, sexual orientation, and more: Sexual diversity in Alzheimer's research needs a new lens to achieve inclusive research and generalizable results

2024-4-1

Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes

2024-4-1

Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling

2024-4-1

Clinical value of Alzheimer's disease biomarker testing

2024-4-1

Awareness and cognitive rehabilitation in Alzheimer's disease and frontotemporal dementia

2024-4-1

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective

2024-4-1

Quantitative systems pharmacology‐based exploration of relevant anti‐amyloid therapy challenges in clinical practice

2024-4-1

Commentary on Greenberg et al., “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions” [<i>Alzheimer's Dement</i>. 2023; 9(4):e12426. doi.org/10.1002/trc2.12426]

2024-1-1

Participant completion of longitudinal assessments in an online cognitive aging registry: The role of medical conditions

2024-1-1

Longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative

2024-1-1

Building digital solutions to support brain health prescribing in primary care: Where to begin?

2024-1-1

The functional role of the pulvinar in discriminating between objective and subjective cognitive impairment in major depressive disorder

2024-1-1

Differentiating MCI from depression through verbal memory scores

2024-1-1

Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease

2024-1-1

Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia

2024-1-1

Evaluation of racial and ethnic heterogeneity in the associations of sleep quality and sleep apnea risk with cognitive function and cognitive decline

2024-1-1

Developing the Healthy Actions and Lifestyles to Avoid Dementia or <i>Hispanos y el ALTo a la Demencia</i> program

2024-1-1